Dostarlimab  (Synonyms: 多塔利单抗; TSR-042)

Dostarlimab (TSR-042) is a humanized anti-PD-1 monoclonal antibody. Dostarlimab binds with high affinity to human PD-1 and competitively inhibits its interaction with its ligands, PD-L1 and PD-L2, with IC₅₀s of 1.8 and 1.5 nM, respectively^[1].

Human IgG4 kappa

Human IgG4 (S228P) kappa, Isotype Control

Humanized

IC50: 1.5 nM (PD-L2/ PD-1), 1.8 nM (PD-L1/ PD-1)^[1]

Dostarlimab (10-10000 ng/mL) 以剂量依赖的方式与人和食蟹猴 CD3⁺ T 细胞上表达的原生 PD-1 受体结合^[1]。
Dostarlimab (0-375 nM; 48 h) 在人 CD4⁺ T 细胞 MLR 实验中增加 IL-2 的产生，EC₅₀ 大约为 1 nM，在葡萄球菌肠毒素 B (SEB) 刺激的 PBMC 细胞中增加 IL-2 的产生，EC₅₀ 大约为 0.1 nM，增强干扰素 (IFN)-γ 的释放，EC₅₀ 大约为 0.5 nM^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Dostarlimab (200 µg/mouse; i.p.; twice weekly for 35 days) 在人源化小鼠模型中显示出抗肿瘤活性^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

2022215-59-2

液体

Colorless to light yellow

多塔利单抗

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG4 kappa

• [1]. Kumar S, et al. Preclinical characterization of dostarlimab, a therapeutic anti-PD-1 antibody with potent activity to enhance immune function in in vitro cellular assays and in vivo animal models. MAbs. 2021 Jan-Dec;13(1):1954136.  [Content Brief]